3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Persistent Postoperative Pain
1
Obesity
1
Mouth Neoplasms
1
Liver Neoplasms
1
Inflammation
1
Breast Neoplasms
1
Breast Cancer Patient
1
Brain Neoplasms
1
Interventions
epigallocatechin gallate
2
Ascorbic Acid
2
semaglutide
1
microcrystalline cellulose
1
dapagliflozin
1
cytisine
1
bupropion hydrochloride, naltrexone hydrochoride drug combination
1
XENP 1595
1
Vitamin D
1
Topiramate
1
Tirzepatide
1
Tablets
1
Spirometry
1
Specimen Handling
1
Selenium
1
Saline Solution
1
Resistance Training
1
Reperfusion
1
Qsymia
1
Probiotics
1
Pregabalin
1
Platelet Count
1
Plastic Surgery Procedures
1
Phentermine
1
Omeprazole
1
Naltrexone
1
Losartan
1
Liraglutide
1
Ketorolac
1
Ischemic Preconditioning
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Inflammation
×
Pregabalin
×
1 year
×
Clear all
NCT06150898
2025-06-13
KePreSt
Jules Bordet Institute
Phase 2
Recruiting
112 enrolled